Prospective short-term effects of glucocorticoid treatment on glucose and lipid metabolism in Japanese

Internal Medicine

Volumn 49, Issue 10, 2010, Pages 897-902

  Kuroki, Yasuo ^a   Kaji, Hiroshi ^b   Kawano, Seiji ^c   Kanda, Fumio ^b   Takai, Yutaka ^d   Kajikawa, Michiko ^e   Sugimoto, Toshitsugu ^f  

^a Kobe Century Memorial Hospital   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KOBE UNIVERSITY HOSPITAL   (Japan)

^d Kobe University   (Japan)

^e YODOGAWA CHRISTIAN HOSPITAL   (Japan)

^f SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Cholesterol; Glucocorticoid; Glucose; Insulin

Indexed keywords

CHOLESTEROL; GLUCOCORTICOID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOREACTIVE INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; PREDNISOLONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIET RESTRICTION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; MALE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; JAPAN; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 77952945255     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3161     Document Type: Article

References (28)

1. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96: 23-43, 2002.
2. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: toward expansion of therapeutic options? Eur J Clin Invest 39: 81-93, 2009.
3. Bowes SB, Benn JJ, Scobie IN, Umpleby AM, Lowy C, Sonksen PH. Glucose metabolism in patients with Cushing's syndrome. Clin Endocrinol 34: 311-316, 1991.
4. Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients 901 with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88: 2527-2533, 2003.
5. Ettinger WH, Klinefelter HF, Kwiterovitch PO. Effect of short-term, low-dose coirticosteroids on plasma lipoprotein levels. Atherosclerosis 63: 167-172, 1987.
6. Salazar A, Mañá J, Pintó X, Argimón JM, Hurtado I, Pujol R. Corticosteroid therapy increases HDL-cholesterol concentrations in patients with active sarcoidosis and hypopalphalipoproteinemia. Clin Chim Acta 320: 59-64, 2002.
7. Fukuyama K, Ohara T, Hirota Y, et al. Association of the 112A/C polymorphism of the uncoupling protein 1 gene with insulin resistance in Japanese individuals with type 2 diabetes. Biochem Biophys Res Commun 339: 1212-1216, 2006.
8. Larsson H, Ahren B. Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. Diabetologia 42: 936-943, 1999.
9. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 40: 1439-1448, 1997.
10. Rizza RA, Mandarino JJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 54: 131-138, 1982.
11. Schmoon H, Soman V, Sherwin RS. The influence of acute physiological increments of cortisol on fetal metabolism and insulin binding to monocytes in normal humans. J Clin Endocrinol Metab 50: 495-501, 1980.
12. Kalhan SC, Adam PA. Inhibitory effect of prednisone on insulin secretion in man: model for duplication of blood glucose concentration. J Clin Endocrinol Metab 41: 600-610, 1975.
13. Van Raalte DH, Mari A, Bunck MC, et al. Acute and subacute exposure to glucocorticoids differentially impair various aspects of beta-cell function I healthy males (1468-P). 68th Sesseions American Diabetes Association, San Francisco, 2008.
14. Wajngot A, Giacca A, Grill V, Vranic M, Efendic S. The diabetogenic effects of glucocorticoids are more pronounced in low-than in high-insulin responders. Proc Natl Acad Sci USA 89: 6035-6039,1992.
15. Beard JC, Halter JB, Best JD, Pfeifer MA, Porte D Jr. Dexamethasone-induced insulin resistance enhances B cell responsiveness to glucose level in normal men. Am J Physiol 247: E592-E596, 1984.
16. Grill V, Pignon J, Hartling SG, Binder C, Efendic S. Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. Metabolism 39: 251-258, 1990.
17. Matsumoto K, Yamasaki H, Akazawa S, et al. High-dose but not low-dose devamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab 81: 2621-2626, 1996.
18. Zarkovic M, Beleslin B, Ciric J, et al. Glucocorticoid effect on insulin sensitivity: a time frame. J Endocrinol Invest 31: 238-242, 2008.
19. Ettinger WH Jr, Hazzard WR. Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endocrinol Metab 67: 425-428, 1988.
20. Henkin Y, Como JA, Oberman A. Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice. JAMA 267: 961-968, 1992.
21. Leong KH, Koh ET, Feng PH, Boey MO. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 21: 1264-1267,1994.
22. Garcia-Gomez C, Nolla JM, Valverde J, Narváez J, Corbella E, Pintó X. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest 38: 686-692,2008.
23. Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis. The third national health and nutrition examination survey. J Rheumatol 32: 2311-2316, 2005.
24. Ewart HS, Carroll R, Severson DL. Lipoprotein lipase activity in rat cardiomyocytes is stimulated by insulin and dexamethasone. Biochem J 327: 439-442, 1997.
25. Dolinsky VW, Douglas DN, Lehner R, Vance DE. Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and reesterification by the glucocorticoid dexamethasone. Biochem J 378: 967-974, 2004.
26. Kuusi T, Saarinen P, Nikkila EA. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein 2 in man. Atherosclerosis 36: 589-593, 1980.
27. Berg AI, Nilsson-Ehle P. Direct effects of corticotropin on plasma lipoprotein metabolism in man-studies in vivo and in vitro. Metabolism 43: 90-97, 1994.
28. Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res Ther 8: R82, 2006.